Liver Toxicity Risk Management Should Consider Timing Of Signal, FDAer Says
Executive Summary
Risk management programs for drug-induced hepatotoxicity should take into account timing and level of exposure, FDA Office of Drug Safety Division of Drug Risk Evaluation Director Mark Avigan, MD, said
You may also be interested in...
FDA Will Fund Research On “Critical Path” Of Drug Development
FDA's "Critical Path" initiative will redirect the agency's research funding towards identifying and alleviating some major barriers to drug development
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials